Loading
A phase 1/2 trial of CAR-GPC3 T Cells in hepatocellular carcinoma, non-small-cell lung cancer, merkel cell carcinoma and sarcomas, run by Sotio Biotech Inc., active and no longer recruiting.
BOXR1030 T Cells in Subjects With Advanced GPC3-Positive Solid Tumors is a phase 1/2 interventional study registered as NCT05120271 by Sotio Biotech Inc., with 7 participants enrolled, started 2022-10-26 and due to reach its primary completion in 2025-10-24. Interventions recorded: CAR-GPC3 T Cells.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Sarcomas (soft tissue, bone, GIST), Non-small-cell lung cancer and the tag pipeline.
Shares Sarcomas (soft tissue, bone, GIST), Non-small-cell lung cancer and the tag pipeline.
Shares Hepatocellular carcinoma, Non-small-cell lung cancer and the tag pipeline.
Shares Hepatocellular carcinoma, Non-small-cell lung cancer and the tag pipeline.
Shares Sarcomas (soft tissue, bone, GIST) and the tag pipeline.
Shares Hepatocellular carcinoma and the tag pipeline.
Shares Hepatocellular carcinoma, Non-small-cell lung cancer and the tag pipeline.
Shares Merkel cell carcinoma and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/